Drug companies Aurobindo Pharma, Sun Pharma and Dr Reddy's Laboratories have bagged US health watchdog's sanction to market generic Plavix, utilized in treating heart illnesses, in the US market.

Dr Reddy's stated that it has rolled out clopidogrel tabs in US after bagging nod from the USFDA.

Clopidogrel pills are the generic edition of Sanofi Aventis' Plavix tabs.

Dr Reddy's has got nod for pills in potencies of 75 mg and 300 mg, whereas Aurobindo Pharma and Sun Pharma got USFDA's sanction for the pills in 75 mg strength.

As per IMS Health sales facts, clopidogrel tabs registered sales of approximately $ 6.74 billion in the United States for the twelve month period ended March, 2012.

Dr Reddy's stated that its 300 mg clopidogrel pills have been given 180-days of marketing exclusivity in the United States.

It also said that its product in 75 mg potency is obtainable in bottle count sizes of 30, 90 and 500 whereas 300 mg potency medication is obtainable in blister packs of 30 count.

Dr Reddy's shares, on May 18, closed at Rs 1660.55 after shedding 0.08% on the Bombay Stock Exchange (BSE).

While scrips of Aurobindo Pharma closed up 1.79%, on the BSE at Rs 108.05, those of Sun Pharma gained 0.27% at Rs 581.80 on the BSE.